Epidermal Growth Factor Receptor (EGFR) (pTyr845) antibody

Antigen: Epidermal Growth Factor Receptor (EGFR)

Synonyms: ERBB, HER1, mENA, ERBB1, PIG61, Wa5, wa2, Erbb, Errp, wa-2, AI552599, 9030024J15Rik, ErbB-1, C-erb, D-EGFR, D-Egf, DEGFR, DER, DER flb, DER/EGFR, DER/faint little ball, DER/top, DER/torpedo, DmHD-33, EFG-R, EGF-R, EGFR, EK2-6, Egf, El, Elp, Elp-1, Elp-B1, Elp-B1RB1, HD-33, Torpedo/DER, Torpedo/Egfr, c-erbB, d-egf-r, dEGFR1, flb, l(2)05351, l(2)09261, l(2)57DEFa, l(2)57EFa, l(2)57Ea, pnt, top, top/DER, top/flb, DmelCG10079, CG10079, egfr, EGFR12, EGFR15, egfr1, Erbb2

Binding Site: pTyr845

Clonality: Monoclonal (12A3)

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), ELISA

Catalog no.: ABIN967602

Additional Information

Alternative name: EGF Receptor

Immunogen: Phosphorylated Human EGF Receptor Peptide

Cross-Reactivity: Mouse (Murine), Rat (Rattus)

Format: Liquid

Isotype: IgG1, kappa

Clone: 12A3

Description: Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. In addition, c-Src-dependent phosphorylations at other sites, such as tyrosine 845 (Y845) in the kinase domain, regulate the receptor's kinase activity. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies.
The 12A3 monoclonal antibody recognizes the phosphorylated Y845 in the protein tyrosine kinase domain of human EGFR.

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
3. Please refer to us for technical protocols.

Molecular Weight: 175 kDa

Comments:

Related Products: ABIN967389

Synonyms: ERBB, HER1, mENA, ERBB1, PIG61, Wa5, wa2, Erbb, Errp, wa-2, AI552599, 9030024J15Rik, ErbB-1, C-erb, D-EGFR, D-Egf, DEGFR, DER, DER flb, DER/EGFR, DER/faint little ball, DER/top, DER/torpedo, DmHD-33, EFG-R, EGF-R, EGFR, EK2-6, Egf, El, Elp, Elp-1, Elp-B1, Elp-B1RB1, HD-33, Torpedo/DER, Torpedo/Egfr, c-erbB, d-egf-r, dEGFR1, flb, l(2)05351, l(2)09261, l(2)57DEFa, l(2)57EFa, l(2)57Ea, pnt, top, top/DER, top/flb, DmelCG10079, CG10079, egfr, EGFR12, EGFR15, egfr1, Erbb2

Application Details

Concentration: 0.5 mg/ml

Purity: Purified

Purification: Purified from tissue culture supernatant or ascites by affinity chromatography.

Buffer: Aqueous buffered solution.

Preservative: 0.09% Sodium azide.

Storage: Store undiluted at 4°C.

Restrictions: For Research Use only

Images

Western blot analysis of EGF Receptor (pY845) in human epidermis. Lysates from control (first panel) and EGF-treated (second panel) human A-431 epidermoid carcinoma were probed with purified mouse anti-EGF Receptor (pY845) monoclonal antibody at concentrations of 0.1, 0.05, and 0.025 µg/ml (lanes 1, 2, and 3, respectively). EGF Receptor (pY845) is identified as a band of 175 kDa in the treated cells.

EGF Receptor (pY845) staining on tonsil. Fresh human tonsil was incubated in 5 mM Pervanadate solution for 2 hours, then fixed in formalin and processed. Following antigen retrieval with BD Retrievagen A buffer, the sections were either left untreated (first panel) or treated with a phosphatase to eliminate all phosphorylation (second panel). The tissue sections were stained with purified Mouse anti-EGF Receptor (pY845) with Hematoxylin counterstaining. No staining was seen on sections of unstimulated tonsil (data not shown). Original magnification: 20X.

Publications

Product: Biscardi, Maa, Tice et al.: "c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function." in: The Journal of biological chemistry, Vol. 274, Issue 12, pp. 8335-43, 1999 (PubMed).

Olayioye, Neve, Lane et al.: "The ErbB signaling network: receptor heterodimerization in development and cancer." in: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, 2000 (PubMed).

Moro, Dolce, Cabodi et al.: "Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines." in: The Journal of biological chemistry, Vol. 277, Issue 11, pp. 9405-14, 2002 (PubMed).

Wu, Graves, Gill et al.: "Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation." in: The Journal of biological chemistry, Vol. 277, Issue 27, pp. 24252-7, 2002 (PubMed).

Mendelsohn, Baselga: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 14, pp. 2787-99, 2003 (PubMed).

Boerner, Demory, Silva et al.: "Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II." in: Molecular and cellular biology, Vol. 24, Issue 16, pp. 7059-71, 2004 (PubMed).